By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hutchison China MediTech (Chi-Med) 

21st Floor, Hutchison House
10 Harcourt Road
Hong Kong      China
Phone: 852-2121-8200 Fax: 852-2121-8281


Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases.




CEO: Christian Hogg

CFO: Johnny Cheng

CSO: Weiguo Su

Key Statistics

Ownership: Subsidiary

Web Site: Hutchison China MediTech (Chi-Med)


Company News
Hutchison China MediTech (Chi-Med): Director's Share Dealing 8/9/2016 11:03:52 AM
Hutchison China MediTech (Chi-Med) 2016 Interim Results 8/3/2016 9:53:02 AM
Hutchison China MediTech (Chi-Med): Change Of Non-Executive Directors 8/2/2016 9:38:26 AM
Hutchison China MediTech (Chi-Med) Reports Interim Results For The Six Months Ended June 30, 2016, Provides 2016 Financial Guidance And Updates Shareholders On Key Clinical Programs 8/2/2016 8:13:34 AM
Chi-Med to Invest Up to $50 Million in Amended Savolitinib Deal With AstraZeneca PLC (AZN) 8/1/2016 7:50:04 AM
Hutchison China MediTech (Chi-Med) To Announce 2016 HY Financial Results 7/5/2016 12:36:44 PM
Hutchison China MediTech (Chi-Med) Earns $10 Million Milestone From AstraZeneca PLC (AZN) In Lung Cancer Trial 6/21/2016 2:58:31 PM
Hutchison China MediTech (Chi-Med) Release: Savolitinib Global Phase II Trial Initiated In EGFR Mutant Non-Small Cell Lung Cancer 6/20/2016 11:06:20 AM
Hutchison China MediTech (Chi-Med) Webcast Presentation Now Available For On-Demand Viewing: dbVIC - Deutsche Bank (DB) ADR Virtual Investor Conference 6/14/2016 11:29:52 AM
Hutchison China MediTech (Chi-Med) To Present At The dbVIC - Deutsche Bank (DB) ADR Virtual Investor Conference On June 10, 2016 6/6/2016 12:51:19 PM